FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Dillon Michael J.

2. Date of Event Requiring Statement (MM/DD/YYYY)
5/1/2017 

3. Issuer Name and Ticker or Trading Symbol

PLx Pharma Inc. [PLXP]

(Last)        (First)        (Middle)

8285 EL RIO STREET, STE. 130

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
VP, Sales and Marketing /

(Street)

HOUSTON, TX 77054       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option   5/1/2018   (1) 5/1/2027   Common Stock   45000   $7.975   D    

Explanation of Responses:
(1)  The Reporting Person was awarded 45,000 employee stock options on May 1, 2017 under the Issuer's 2015 Omnibus Incentive Plan. One-third of the grant becomes exercisable on the first anniversary of the grant date, with the remainder becoming exercisable in quarterly installments over the next two years following the first anniversary of the grant date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Dillon Michael J.
8285 EL RIO STREET
STE. 130
HOUSTON, TX 77054


VP, Sales and Marketing

Signatures
Natasha Giordano, as Attorney-in-Fact for Michael J. Dillon 5/5/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more PLx Pharma Charts.
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more PLx Pharma Charts.